Condition: Colon Cancer · Sponsor: Jiangsu Famous Medical Technology Co., Ltd.
This study is designed as a multi-center, randomized, double-blind, placebo-controlled trial. Subjects in the intervention group will be treated with XLJDOD compound granule. Subjects in the control group will be treated with placebo (XLJDOD mimetic agent).
This description comes directly from the study's public registry record.
Yujia Wang · 18120192802 · 1217909635@qq.com
Always discuss trial participation with your own doctor first.
| Jiangsu Province Hospital of Traditional Chinese Medicine | Nanjing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05709249